

**CLAIMS**

1. P2X purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases, preferably multiple sclerosis, in mammals including man.  
5
2. P2X purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases in accordance with claim 1 characterised because the purinergic receptor is preferably a P2X7 receptor.  
10
3. P2X purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases in accordance with claim 1 characterised because the antagonist is a wide spectrum antagonist of P2X receptors or a selective antagonist of a P2X7 receptor, such as o-ATP.  
15
4. P2X purinergic receptor antagonist for the treatment of demyelinating and autoimmune diseases in accordance with claim 1 and 3 characterised because the aforementioned antagonist can be selected from between PPADS, iso-PPADS, Suramin, Evans Blue, NF023, NF279, BBG, NF449, o-ATP, KN62, PPNDS, RB2, MRS2220, Ip51, TNP-ATP or HMA.  
20
5. Use of an antagonist of P2X purinergic receptors in the preparation of a drug for the treatment of demyelinating and autoimmune diseases, preferably multiple sclerosis, in mammals including man.  
25
6. Use of an antagonist of P2X purinergic receptors in accordance with claim 5 characterised because the aforementioned purinergic receptors are preferably P2X7 receptors.
- 30 7. Use of an antagonist of P2X purinergic receptors in accordance with claim 5 characterised because the aforementioned antagonist is a wide spectrum antagonist for P2X receptors or a selective antagonist of a P2X7 receptor, such as o-ATP.
- 35 8. Use of an antagonist of P2X purinergic receptors in accordance with claim

5 to 7 characterised because the aforementioned antagonist can be selected from between PPADS, iso-PPADS, Suramin, Evans Blue, NF023, NF279, BBG, NF449, o-ATP, KN62, PPNDS, RB2, MRS2220, Ip51, TNP-ATP or HMA.

5

9. A pharmaceutical composition which comprises of at least one P2X purinergic receptor antagonist and at least one pharmaceutically acceptable excipient.

10 10. A pharmaceutical composition in accordance with claim 9 characterised because the antagonist is a wide spectrum antagonist for P2X receptors or a selective antagonist of a P2X7 receptor, such as o-ATP.

15 11. A pharmaceutical composition in accordance with claim 9 to 10 characterised because the aforementioned antagonist is selected from between PPADS, iso-PPADS, Suramin, Evans Blue, NF023, NF279, BBG, NF449, o-ATP, KN62, PPNDS, RB2, MRS2220, Ip51, TNP-ATP or HMA.